Federal timeline for peptide compounding, July 2026
This page carries the current federal facts as of late July 2026. Most of the internet has these wrong. Peptides are not legal again. They are not FDA approved. Access has not been restored. Read the dates and the vote counts, not the headlines.
February 27, 2026
The Department of Health and Human Services announced its intent to move about fourteen peptides from Category 2 to Category 1. This was an announcement, not a rule. Nothing changed on this date for prescribers.
April 15, 2026
The FDA removed twelve peptides from Category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, GHK-Cu injectable, KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500. Removal from a prohibition list is not the same as being added to an authorization list. These twelve peptides now sit in a gap: not prohibited, not authorized, and not lawfully compoundable under 503A yet.
July 23 and 24, 2026
The Pharmacy Compounding Advisory Committee held a two day meeting and voted on six peptides. Committee votes are advisory. FDA rulemaking is pending and usually takes eight to twenty four months.
What is on Category 1 today
Only GHK-Cu non-injectable and Vasoactive Intestinal Peptide sit on Category 1 as of July 2026. Everything else in the news cycle is either a recommendation, a removal, or a proposal.